亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Melanoma chemoprevention

詳細技術說明
None
*Abstract
BackgroundMelanoma incidence has been increasing rapidly over the past decades. Advanced melanoma is generally refractory to available therapies, and a significant portion will develop distant metastases even with early intervention. Thus, exploration of preventive strategies for melanoma is necessary.Chemoprevention may be one such approach, which has remained relatively unexplored for melanoma. While survival rates for melanoma are excellent when discovered early, the prognosis associated with more advanced disease remains for very poor, thus efforts are warranted to identfify means of primary melanoma prevention. Given the continually rising incidence of melanoma, the ineffectiveness of UV radiation protective strategies and the prevalence of genetic pre-disposing factors, chemoprevention serves as an attractive strategy for primary prevention of melanoma.Technology DescriptionSulforaphane (SFN) is a naturally occurring compound found in cruciferous vegetables such as broccoli, cabbage and cauliflower among many others. Sulforaphane is renowned for its anti-cancer properties and is easily isolated from natural sources.John Kirkwood and colleagues have identified a dosing range and mechanism of action whereby sulforaphane (SFN) can act has a chemopreventative for individuals with apredisposition to melanoma. They have also identified a mechanism of action and possible biomarkers for the progression of atypical nevi to melanoma. Formulations, dosing, and methods of diagnosis and prevention and use are available for licensing.Applications* Prevent melanoma progression* Reduce progression of atypical nevi* Reduce appearance of melanoma precursor lesionsAdvantages* Prevents development of melanoma* Natural product with no toxicity or side effects* Delivered orally and is safe and well tolerated* Effectiveness not limited to patients with specific mutations (ie B-Raf)Stage of Development* Tumor xenograft data available* Phase I study underway in patients with large numbers of atypical neviUS Provisional Patent Application filed
*Principal Investigation

Name: Jan Beumer

Department: Pharm-Pharmaceutical Science


Name: John Kirkwood, Professor of Medicine & Vice-Chairman

Department: Med-Medicine


Name: Shivendra Singh

Department: Med-Pharmacology and Chemical Biology

國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備